Wave Life Sciences Ltd.
WVE
Price:
$5.97
Market Cap:
$744.69M
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a ...[Read more]
Industry
Biotechnology
IPO Date
2015-11-11
Stock Exchange
NASDAQ
Ticker
WVE
The ROE as of September 2024 (TTM) for Wave Life Sciences Ltd. (WVE) is -657.91%
According to Wave Life Sciences Ltd.’s latest financial reports and current stock price. The company's current ROE is -657.91%. This represents a change of 193.79% compared to the average of -223.94% of the last 4 quarters.
Wave Life Sciences Ltd. (WVE) Historical ROE (quarterly & annually)
How has WVE ROE performed in the past?
The mean historical ROE of Wave Life Sciences Ltd. over the last ten years is -118.56%. The current -657.91% ROE has changed 454.93% with respect to the historical average. Over the past ten years (40 quarters), WVE's ROE was at its highest in in the March 2022 quarter at 70.82%. The ROE was at its lowest in in the June 2024 quarter at -748.76%.
Average
-118.56%
Median
-151.08%
Minimum
-376.16%
Maximum
358.88%
Wave Life Sciences Ltd. (WVE) ROE by Quarter and Year
Discovering the peaks and valleys of Wave Life Sciences Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 228.40%
Maximum Annual ROE = 358.88%
Minimum Annual Increase = -703.48%
Minimum Annual ROE = -376.16%
| Year | ROE | Change |
|---|---|---|
| 2023 | -121.07% | -133.74% |
| 2022 | 358.88% | -195.41% |
| 2021 | -376.16% | 107.71% |
| 2020 | -181.10% | -35.70% |
| 2019 | -281.64% | 40.86% |
| 2018 | -199.94% | 173.97% |
| 2017 | -72.98% | 77.65% |
| 2016 | -41.08% | 228.40% |
| 2015 | -12.51% | -95.15% |
| 2014 | -257.97% | -703.48% |
Wave Life Sciences Ltd. (WVE) Average ROE
How has WVE ROE performed in the past?
The current ROE of Wave Life Sciences Ltd. (WVE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-46.12%
5-year avg
-120.22%
10-year avg
-118.56%
Wave Life Sciences Ltd. (WVE) ROE vs. Peers
How is WVE’s ROE compared to its peers?
Wave Life Sciences Ltd.’s ROE is greater than Arrowhead Pharmaceuticals, Inc. (-172.90%), greater than CytomX Therapeutics, Inc. (-27.44%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than VectivBio Holding AG (-56.92%), greater than Icosavax, Inc. (-41.24%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than iTeos Therapeutics, Inc. (-18.19%), greater than TScan Therapeutics, Inc. (-59.83%), greater than ProQR Therapeutics N.V. (-55.21%), less than Alnylam Pharmaceuticals, Inc. (47.92%), greater than Blueprint Medicines Corporation (-85.25%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Mereo BioPharma Group plc (-63.39%),
| Company | ROE | Market cap |
|---|---|---|
| -172.90% | $2.57B | |
| -27.44% | $94.91M | |
| -121.55% | $113.14M | |
| -47.64% | $8.20M | |
| -56.92% | $1.06B | |
| -41.24% | $769.04M | |
| -139.02% | $4.39B | |
| -18.19% | $435.89M | |
| -59.83% | $307.25M | |
| -55.21% | $149.07M | |
| 47.92% | $34.73B | |
| -85.25% | $5.46B | |
| -39.58% | $665.72M | |
| -46.15% | $181.44M | |
| -24.63% | $152.90M | |
| -68.93% | $376.41M | |
| 32.93% | $120.01M | |
| -122.70% | $1.21B | |
| -63.39% | $681.18M |
Build a custom stock screener for Wave Life Sciences Ltd. (WVE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Wave Life Sciences Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Wave Life Sciences Ltd. (WVE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Wave Life Sciences Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Wave Life Sciences Ltd.'s ROE?
How is the ROE calculated for Wave Life Sciences Ltd. (WVE)?
What is the highest ROE for Wave Life Sciences Ltd. (WVE)?
What is the 3-year average ROE for Wave Life Sciences Ltd. (WVE)?
What is the 5-year average ROE for Wave Life Sciences Ltd. (WVE)?
How does the current ROE for Wave Life Sciences Ltd. (WVE) compare to its historical average?